Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The biggest fallers on the FTSE 100 were Croda International, down 301p at 2,598p; Rentokil Initial, down 12.9p at 348.1p; ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Facing a $70 billion market loss, Novo Nordisk appointed Maziar Mike Doustdar as its new CEO to navigate intensifying ...

Hims & Hers, which markets compounded versions of semaglutide through its telehealth platform, released clinical data shortly after Novo’s statement. The data showed that users of its compounded GLP-1 ...